Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.

Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...

Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.